Abstract:Abstract Background Ustekinumab (UST) is a monoclonal antibody that binds to the p40 subunit shared by pro-inflammatory interleukins 12 and 23. UST has demonstrated efficacy for the induction and maintenance of remission in patients with Crohn’s disease (CD). A proportion of patients with CD do not respond to UST at the standard dose of 90 mg every 8 weeks. Methods A multi-centre retrospective study of CD patient who commenced UST therapy at two specialist tertiary referral centres between October 2012 and March 2021 was performed. Patient demographics, baseline characteristics, medication history and disease behaviour were characterised. Duration of UST therapy and UST dose escalation were documented. UST therapy persistence, was considered a proxy for treatment response, and was expressed as time to discontinuation of UST therapy. The study evaluated whether UST dose optimisation was associated with increased UST therapy persistence; and clinical factors associated with UST therapy persistence. Optimised dosing was defined as a dosing regimen of UST 90mg at less than an 8-weekly interval. Statistical analysis was performed using survival analysis and multivariate cox logistic regression with effect of covariates on outcome expressed as odds ratios (OR). Results 133 patients commenced UST during the study period (age [mean, range] 39 years, 16-79; 59% female; disease duration [mean, range] 12.4 years, 1-35). 99% of patients had failed at least 1 biologic and 72 patients (54%) required dose escalation during the study period. The mean duration of UST therapy was 74 weeks (range 2-427). 75 (56%) patients were still receiving UST at end of study period. Survival analysis demonstrated that there was no significant difference in UST persistence between patients receiving standard and optimised UST dosing regimens, p=0.58. Patients with early UST dose optimisation (within 6 months of therapy initiation) had increased UST therapy persistence, p=0.003. A multivariate regression analysis demonstrated that early UST dose optimisation (within 6 months of therapy initiation) was independently associated with a longer time to UST therapy discontinuation (OR 0.31 (95%CI 0.15-0.68), p=0.003). Neither disease duration (OR 1.11, p=0.66), male sex (OR 0.91, p=0.83), concomitant immunomodulator use (OR 1.03, p=0.95), perianal disease (OR 1.09, p=0.85), smoking status (OR 1.16, p=0.68) nor previous surgery (OR 1.47, p=0.33) were independently associated with time to UST therapy discontinuation. Conclusion UST is an effective treatment for CD patients with prior biologic therapy exposure. Optimised UST dosing regimens are frequently utilised in routine clinical practice. There appears to be an increased likelihood of treatment success with early UST dose optimisation.

P624 Development and Validation of a Clinical Decision Support Tool to Predict Outcomes of ustekinumab Treatment in Patients with Crohn’s Disease

Short-term efficacy of ustekinumab in patients with Crohn’s disease and intestinal stricture

Reasons and Factors Contributing to Chinese Patients’ Preference for Ustekinumab in Crohn’s Disease: A Multicenter Cross-Sectional Study

P542 Clinical decision support tool guided selective intensive induction strategy of ustekinumab in patients with Crohn’s disease: real-world evidence

Clinical Decision Support Tool Guided Selective Intensive Induction Strategy of Ustekinumab in Patients with Crohn's Disease: Real-World Evidence

A novel nomogram for predicting endoscopic remission in refractory Crohn�s disease with ustekinumab administration

P1085 Machine learning to predict the efficacy of ustekinumab for ulcerative colitis

Intestinal mRNA expression profiles associated with mucosal healing in ustekinumab-treated Crohn's disease patients: bioinformatics analysis and prospective cohort validation

Ustekinumab Trough Concentration Affects Clinical and Endoscopic Outcomes in Patients with Refractory Crohn’s Disease: a Chinese Real-World Study

Discovery of intestinal mRNA expression profiles correlated with mucosal healing of ustekinumab patients with Crohn’s disease: bioinformatics analysis and prospective cohort validation

P552 Clinical factors associated with ustekinumab therapy persistence in a refractory Crohn’s disease cohort

P576 Fecal calprotectin could predict clinical and endoscopic response to ustekinumab therapy

P363 Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn’s disease treated with ustekinumab

P669 Efficacy of Ustekinumab-based integrated medicine therapy in patients with symptomatic stricturing Crohn's disease: a multicentre, prospective, observational cohort study

[Clinical remission and transmural healing of ustekinumab in patients with Crohn's disease].

P1022 One-year safety and effectiveness of ustekinumab in patients with Crohn’s disease: The K-STAR study

P917 Ustekinumab and immunomodulatory combination therapy is more effective than Ustekinumab monotherapy to prevent relapse in Crohn’s patients classified as low to intermediate-probability responders by UST-CDST

P886 Ustekinumab concentrations in induction are associated with mid-term endoscopic outcomes in patients with inflammatory bowel disease

P574 Clinical outcomes in extending of injection period of ustekinumab from every 8 to 12 weeks in patients with Crohn’s disease (CD-EXTEND Study)

Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn's disease treated with ustekinumab

P707 Real-world Long-term efficacy of ustekinumab in the treatment of Perianal Fistulizing Crohn's disease: Results from a single-center retrospective study